Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
Investigate the safety and tolerability of umbilical cord-derived allogeneic mesenchymal stem
 cells to treat patients with Bradykinesia.
While the pathophysiological changes that result in the symptoms of bradykinesia are poorly
 understood, an inflammatory component appears to be involved. Human umbilical cord-derived
 allogeneic mesenchymal stem cells have documented anti-inflammatory properties, which suggest
 these cells may be effective at treating Bradykinesia. It is understood that perinatal
 products are potent immune modulators. It is believed that the positive symptomatic effects
 are secondary to the modulation of the immune system, and specifically the reduction in
 pathological inflammation. The study is designed to evaluate the safety and tolerability of
 umbilical cord-derived allogeneic mesenchymal stem cells to treat patients with Bradykinesia.
Inclusion Criteria:

 -  Age of 55 years or older

 -  Clinically diagnosed with Parkinsonism

 -  All subjects, or their authorized representatives, must be adequately informed and
 understand the nature and risks of the study and must be able to provide a signature
 and date in the Informed Consent Form (ICF).

 -  Clinically diagnosed bradykinesia for at least 3 months prior to baseline visit.

 -  On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4
 weeks prior to baseline.

 -  Women of child-bearing potential must undergo a negative serum pregnancy test at the
 screening assessment.

 -  Subjects, or their representatives, must be able to communicate effectively with the
 study staff.

 -  Subjects, or their authorized representatives, must certify that they are able and
 willing to follow all protocol requirements and study restrictions.

 Exclusion Criteria:

 -  Subjects who are intolerant of, or unwilling to, participate in all procedures
 required of this protocol.

 -  Subjects who cannot tolerate a venipuncture and/or have adequate venous access.

 -  Inability to ambulate 100 feet independently with or without an assistive device.

 -  Subjects who have a history of allergy, hypersensitivity, or intolerance to any
 medications, components, or excipients of the investigational product or procedures,
 and which cannot be resolved by the staff conducting the study.

 -  Subjects with a known diagnosis of Atypical Parkinsonian Syndrome e.g.:

 1. Dementia with Lewy Bodies;

 2. Progressive Supranuclear Palsy;

 3. Corticobasal Degeneration;

 4. Multiple System Atrophy;

 5. Other Neurodengerative Conditions.

 -  Head trauma related to the onset of bradykinesia symptoms.

 -  History of repeated head injury, hydrocephalus, encephalitis, or cerebral tumors.

 -  Choreoathetosis

 -  Any documented abnormality in the brain by CT or MRI, which might contribute to the
 motor function, e.g., stroke, tumor, or other space-occupying lesions, hydrocephalus,
 or encephalomalacia.

 -  Known history of serum or plasma progranulin level < 110.9 ng/mL.

 -  Disease associated mutation in TDP-34, PGRN, CHMPB2, or VCP genes or any other FTLD
 Causative genes.

 -  Intracranial operation, e.g., pallidotomy, thalamotomy, and/or deep brain stiumulation
 surgery.

 -  Other known neurodegenerative diseases not underlying the bradykinesia, e.g.,
 Spinocerellar Atropy (SCA), Wilson's Disease, or Amyotrphic Lateral Sclerosis (ALS).

 -  History of other significant neurological or physciatric disorders including, but not
 limited to, Alzheimer's disease, Lewy Body Dementia, Prior Disease, stroke, or seizure
 disorder.

 -  Psychiatric illness that is unrelated to the Bradykinesia, e.g., severe bipolar or
 unipolar depression.

 -  History of neurotoxin exposure.

 -  History of REM behavior disorder.

 -  Patients with Hepatocellular Carcinoma (HCC).

 -  Acute liver failure or episode of hepatic encephalopthy.

 -  Systolic blood pressure greater than 180 or less than 90 mmHg.

 -  Diastolic blood pressure greater than 105 or less than 50 mmHg.

 -  Presence of QTcprolongation or ECG abnormal at screening and judged to be clinically
 significate by the site investigator.

 -  Clinically significant cardiovascular disease, e.g., cardiac surgery or myocardial
 infarction within the last 6 months, unstable angina, congestive heart failure,
 significant cardaic arrthymia; or cogenitial heart disease.

 -  Early, symptomatic autonomic dysfunction.

 -  Any malignancy (other than non-metasticic basal cell carcinoma of the skin) with 5
 years of screening.

 -  Clinically significant lab abnormalities at screening, including creatinine ≥ 2.5
 mg/dL, vitam B12 below laboratory normal reference range, or TSH above laboratory
 normal reference range.

 -  Current clinically significant hematological, endocrine, cardiovascular, renal,
 heapatic, gastrointestinal, or neurological disease. For the non-cancerconditions, if
 the condition has been stable for at least the past year and is judged by the site
 investigator not to interfere with the patient's participation in the study, the
 patient may be included.

 -  A history of alcohol or substance abuse within 1 year prior to screening and deemed to
 be clinically significant by the site investigator.

 -  An employee or relative of an employee.

 -  Subjects who have donated plasma or platelets or had a significant loss of whole blood
 (480 ml or more) within 30 days.

 -  Subjects who have received blood or blood products within 30 days prior to screening.

 -  Treatment with any investigational drugs or device or participation in an
 investigational drug study within 60 days of screening.

 -  Women of childbearing potential who are not using at least two forms of medically
 recognized contraception.

 -  Female subjects who are pregnant, expecting to become pregnant, or lactating/nursing.

 -  Any subjects who have a clinically significant abnormal laboratory value.

 -  Subjects who have been treated with another research product 30 days prior to the
 screening assessment, or plant to participate in another clinical trial, while in this
 study. If more than 30 days have passed since participation in another clinical trial,
 the study staff must ensure that the subject has recovered from any adverse events
 associated with the research product used.

 -  Subjects who have a history of any other clinically significant disease or disorder
 that in the opinion of the Principal Investigator, may place the subject at risk due
 to participation in the study, or may influence the results of the study.